Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by quietobserveron Oct 09, 2019 3:59pm
80 Views
Post# 30213745

RE:RE:RE:RE:RE:Hmmm new Zacks report

RE:RE:RE:RE:RE:Hmmm new Zacks reportAnd what's up with VFF today -8%??
ProfCornelius wrote: TGOD is unfortunately witnessing first hand how expensive it is to borrow capital now. I hear that the terms they were offered in exchange for borrowing the capital were super expensive and restrictive. No deal = down 20% PROF quote=jayjay2020]
ProfCornelius wrote: Hey guys, That ZACK's 103M consensus Q12020 revenue estimate is in US dollars so upon conversion it comes out to approx. 137M CDN dollars. Of note, you are going to see that this sector is going to go through a brutal capital crunch where many underfunded LP's will start to fail. Capital is extremely tough to get as we are now in the show me stage. The good news is that we have 2 years plus of cash on hand and access to additional capital from the August deal, thanks to Mr Simon. We are in the best shape of all the LP's in all aspects of business and are the most undervalued. Hope that helps, PROF $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Thewanderer wrote: I’ve seen this estimate floating around There is something not accurate here. I don’t think this estimation is for the current quarter. 103 million rev expectation is way too low. Just ccpharma and rest of distribution can match this. But it’s ok, if it is an official estimate, then it looks like we will crush it.

.
quietobserver wrote:  Wall Street expects a year-over-year decline in earnings on higher revenues when Aphria Inc. (APHA - Research Report) reports results for the quarter ended August 2019. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 15. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a po sitive EPS surprise.
Zacks Consensus Estimate
This company is expected to po st quarterly loss of $0.02 per share in its upcoming report, which represents a year-over-year change of -128.6%.
Revenues are expected to be $103.90 million, up 923.7% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
 

 

 
Hey Prof.  The SAFE banking act will help to release some capital.  But that is still uncertain if and when it will pass.  If it does my guess is the banks are going to be selective and look for the LP's which have the best chance of survival.  Those LP's that are shakey will need to pay a premium to lenders to get access to money.  Money won't come cheap. 



[/quote]

Bullboard Posts